Is MYGN or NVAX more profitable?

Novavax has a net margin of -14.73% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -48.24% -8.51% -4.48% Novavax -14.73% -14.82% 1.23%

Does the media refer more to MYGN or NVAX?

In the previous week, Novavax had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 4 mentions for Novavax and 3 mentions for Myriad Genetics. Novavax's average media sentiment score of 0.41 beat Myriad Genetics' score of 0.04 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Novavax 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ZBIO or MYGN?

In the previous week, Zenas BioPharma and Zenas BioPharma both had 3 articles in the media. Zenas BioPharma's average media sentiment score of 0.90 beat Myriad Genetics' score of 0.04 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MNKD or MYGN more profitable?

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -6.63% -11.21% -3.92% Myriad Genetics -48.24% -8.51% -4.48%

Does the media prefer MNKD or MYGN?

In the previous week, MannKind and MannKind both had 3 articles in the media. MannKind's average media sentiment score of 1.17 beat Myriad Genetics' score of 0.04 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OPK or MYGN?

In the previous week, Myriad Genetics had 2 more articles in the media than OPKO Health. MarketBeat recorded 3 mentions for Myriad Genetics and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.74 beat Myriad Genetics' score of 0.04 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Myriad Genetics (MYGN) Competitors

$4.66 +0.16 (+3.56%)

Closing price 06/23/2026 03:57 PM Eastern

Extended Trading

$4.64 -0.03 (-0.54%)

As of 08:56 AM Eastern

Compare

MYGN vs. NVAX, ZBIO, MNKD, OPK, and LXRX

Should you buy Myriad Genetics stock or one of its competitors? MarketBeat compares Myriad Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Myriad Genetics include Novavax (NVAX), Zenas BioPharma (ZBIO), MannKind (MNKD), OPKO Health (OPK), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to Novavax?

Myriad Genetics (NASDAQ:MYGN) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Myriad Genetics presently has a consensus target price of $6.50, indicating a potential upside of 39.48%. Novavax has a consensus target price of $13.00, indicating a potential upside of 44.44%. Given Novavax's stronger consensus rating and higher possible upside, analysts plainly believe Novavax is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

Novavax has lower revenue, but higher earnings than Myriad Genetics. Novavax is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.53	-$365.90M	-$4.30	N/A
Novavax	$596.34M	2.48	$440.30M	-$0.58	N/A

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novavax has a net margin of -14.73% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
Novavax	-14.73%	-14.82%	1.23%

Myriad Genetics has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market.

In the previous week, Novavax had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 4 mentions for Novavax and 3 mentions for Myriad Genetics. Novavax's average media sentiment score of 0.41 beat Myriad Genetics' score of 0.04 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novavax	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Novavax beats Myriad Genetics on 11 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Myriad Genetics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	127.52	-$377.74M	-$8.47	N/A
Myriad Genetics	$824.50M	0.53	-$365.90M	-$4.30	N/A

Zenas BioPharma has a net margin of 0.00% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Myriad Genetics	-48.24%	-8.51%	-4.48%

Zenas BioPharma has a beta of -0.71, suggesting that its stock price is 171% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

Zenas BioPharma currently has a consensus price target of $44.29, indicating a potential upside of 119.24%. Myriad Genetics has a consensus price target of $6.50, indicating a potential upside of 39.48%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Zenas BioPharma is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.0% of Myriad Genetics shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Zenas BioPharma and Zenas BioPharma both had 3 articles in the media. Zenas BioPharma's average media sentiment score of 0.90 beat Myriad Genetics' score of 0.04 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Myriad Genetics beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to MannKind?

MannKind (NASDAQ:MNKD) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

49.6% of MannKind shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 1.9% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Myriad Genetics	-48.24%	-8.51%	-4.48%

MannKind has higher earnings, but lower revenue than Myriad Genetics. MannKind is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.48	$5.86M	-$0.07	N/A
Myriad Genetics	$824.50M	0.53	-$365.90M	-$4.30	N/A

In the previous week, MannKind and MannKind both had 3 articles in the media. MannKind's average media sentiment score of 1.17 beat Myriad Genetics' score of 0.04 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

MannKind currently has a consensus target price of $8.97, indicating a potential upside of 128.21%. Myriad Genetics has a consensus target price of $6.50, indicating a potential upside of 39.48%. Given MannKind's stronger consensus rating and higher possible upside, research analysts plainly believe MannKind is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MannKind beats Myriad Genetics on 10 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OPKO Health has a net margin of -36.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Myriad Genetics	-48.24%	-8.51%	-4.48%

OPKO Health has higher earnings, but lower revenue than Myriad Genetics. OPKO Health is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A
Myriad Genetics	$824.50M	0.53	-$365.90M	-$4.30	N/A

In the previous week, Myriad Genetics had 2 more articles in the media than OPKO Health. MarketBeat recorded 3 mentions for Myriad Genetics and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.74 beat Myriad Genetics' score of 0.04 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

OPKO Health has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

OPKO Health currently has a consensus price target of $1.55, suggesting a potential upside of 6.16%. Myriad Genetics has a consensus price target of $6.50, suggesting a potential upside of 39.48%. Given Myriad Genetics' higher probable upside, analysts plainly believe Myriad Genetics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Myriad Genetics beats OPKO Health on 9 of the 17 factors compared between the two stocks.

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Myriad Genetics had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 3 mentions for Myriad Genetics and 0 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.00 beat Myriad Genetics' score of 0.04 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Positive
Myriad Genetics	Neutral

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Myriad Genetics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$69.64M	13.78	-$50.34M	-$0.07	N/A
Myriad Genetics	$824.50M	0.53	-$365.90M	-$4.30	N/A

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

Lexicon Pharmaceuticals presently has a consensus price target of $4.55, suggesting a potential upside of 110.65%. Myriad Genetics has a consensus price target of $6.50, suggesting a potential upside of 39.48%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Myriad Genetics	-48.24%	-8.51%	-4.48%

Summary

Lexicon Pharmaceuticals beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYGN vs. The Competition

Export

Metric	Myriad Genetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$425.02M	$3.45B	$6.44B	$12.30B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.08	19.75	24.65	23.99
Price / Sales	0.53	331.95	535.11	118.14
Price / Cash	1.19	128.56	44.82	54.51
Price / Book	1.18	8.29	10.70	6.50
Net Income	-$365.90M	$23.85M	$3.56B	$336.88M
7 Day Performance	6.39%	2.87%	0.94%	-0.16%
1 Month Performance	21.99%	2.19%	0.35%	0.76%
1 Year Performance	-7.72%	55.48%	29.67%	28.49%

Myriad Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYGN Myriad Genetics	2.4896 of 5 stars	$4.66 +3.6%	$6.50 +39.5%	-4.1%	$425.02M	$824.50M	N/A	2,700	News Coverage
NVAX Novavax	1.8431 of 5 stars	$9.21 +3.7%	$12.13 +31.7%	+42.6%	$1.46B	$1.12B	N/A	1,990	News Coverage Gap Up
ZBIO Zenas BioPharma	3.7603 of 5 stars	$18.71 -5.5%	$44.29 +136.7%	+113.3%	$1.25B	$10M	N/A	N/A
MNKD MannKind	3.1025 of 5 stars	$4.00 +9.3%	$8.97 +124.2%	+3.4%	$1.13B	$348.97M	N/A	400
OPK OPKO Health	1.2796 of 5 stars	$1.40 -1.4%	$1.55 +10.7%	+15.0%	$1.07B	$606.90M	N/A	1,373	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYGN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Competitors

MYGN vs. NVAX, ZBIO, MNKD, OPK, and LXRX

How does Myriad Genetics compare to Novavax?

Summary

How does Myriad Genetics compare to Zenas BioPharma?

Summary

How does Myriad Genetics compare to MannKind?

Summary

How does Myriad Genetics compare to OPKO Health?

Summary

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Competitors

MYGN vs. NVAX, ZBIO, MNKD, OPK, and LXRX

How does Myriad Genetics compare to Novavax?

Do analysts rate MYGN or NVAX?

Which has better valuation and earnings, MYGN or NVAX?

Do insiders & institutionals believe in MYGN or NVAX?

Is MYGN or NVAX more profitable?

Which has more volatility and risk, MYGN or NVAX?

Does the media refer more to MYGN or NVAX?

Summary

How does Myriad Genetics compare to Zenas BioPharma?

Which has preferable earnings & valuation, ZBIO or MYGN?

Is ZBIO or MYGN more profitable?

Which has more risk & volatility, ZBIO or MYGN?

Do analysts recommend ZBIO or MYGN?

Do institutionals and insiders believe in ZBIO or MYGN?

Does the media refer more to ZBIO or MYGN?

Summary

How does Myriad Genetics compare to MannKind?

Do insiders and institutionals believe in MNKD or MYGN?

Is MNKD or MYGN more profitable?

Which has better valuation and earnings, MNKD or MYGN?

Does the media prefer MNKD or MYGN?

Which has more volatility and risk, MNKD or MYGN?

Do analysts prefer MNKD or MYGN?

Summary

How does Myriad Genetics compare to OPKO Health?

Do institutionals & insiders hold more shares of OPK or MYGN?

Is OPK or MYGN more profitable?

Which has better earnings and valuation, OPK or MYGN?

Does the media prefer OPK or MYGN?

Which has more risk & volatility, OPK or MYGN?

Do analysts prefer OPK or MYGN?

Summary

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Does the media prefer LXRX or MYGN?

Which has higher earnings and valuation, LXRX or MYGN?

Do institutionals & insiders hold more shares of LXRX or MYGN?

Which has more volatility & risk, LXRX or MYGN?

Do analysts recommend LXRX or MYGN?

Is LXRX or MYGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools